This is the first of a 3 part series of talk on high risk smoldering myeloma and its treatments.

Smoldering multiple myeloma (SMM) is an asymptomatic clonal plasma cell disorder. There have been major advances in the diagnosis, prognosis, and management of SMM in the last few years. High risk SMM patients carry a high risk to progression to multiple myeloma. High risk SMM has been recognised as the optimal phase to test early treatment strategies. The upcoming ASCENT trial aims to prevent progression to active myeloma by 30-50% in the high risk to progression SMM patients.

We are talking to Dr. Shaji Kumar Principal Investigator of the trial and Mayo Clinic expert about the nuances of the ASCENT trial.